Home » Topics » BioWorld Science

BioWorld Science
RSS

Zeno Royalties & Milestones presents WEE1hu inhibitors

Sep. 27, 2019

GlaxoSmithKline and ViiV Healthcare patent new compounds for HIV

Sep. 27, 2019

Immutep announces positive interim data from TACTI-002 phase II study

Sep. 27, 2019

Immunicum presents complete topline data from phase II MERECA study

Sep. 27, 2019

First patient dosed in phase IIb ICONA study of icosabutate

Sep. 27, 2019

FDA authorizes first-in-human clinical trial of AZD-0466

Sep. 27, 2019

TRPC4AP identified as gene biomarker candidate in thyroid dysgenesis

Sep. 27, 2019

FABP4 as a novel biochemical marker in diabetic ketoacidosis in children

Sep. 27, 2019

Dual CB1R/iNOS antagonist MRI-1867 ameliorates obesity-induced CKD in vivo

Sep. 27, 2019

BAL-101553 treatment associated with inhibition of CSLC-mediated tumor angiogenesis in vivo

Sep. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...